Antimicrobial treatment of laryngeal leukoplakia

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518793-14-00

Enrollment

Registered

2024-10-30

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laryngeal leukoplakia

Brief summary

disappearance of leukoplakia

Interventions

DRUGDiflucan 100 mg kovat kapselit

DRUGKefexin 500 mg tabletti

DRUGkalvopäällysteinen

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
disappearance of leukoplakia	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026